Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


May 27, 2015 3:04 AM ET

Biotechnology

Company Overview of Tokai Pharmaceuticals, Inc.

Company Overview

Tokai Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing novel proprietary therapies for the treatment of prostate cancer and other hormonally-driven diseases in the United States. Its lead drug candidate includes galeterone, an oral small molecule drug candidate, which is in Phase II clinical trials for the treatment of castration resistant prostate cancer. The company was founded in 2004 and is based in Cambridge, Massachusetts.

One Broadway

14th Floor

Cambridge, MA 02142

United States

Founded in 2004

17 Employees

Phone:

617-225-4305

Key Executives for Tokai Pharmaceuticals, Inc.

Chief Executive Officer, President and Director
Age: 39
Total Annual Compensation: $608.5K
Chief Financial Officer
Age: 33
Total Annual Compensation: $201.7K
Chief Medical Officer and Head of Research & Development
Age: 56
Total Annual Compensation: $408.8K
Compensation as of Fiscal Year 2014.

Tokai Pharmaceuticals, Inc. Key Developments

Tokai Pharmaceuticals, Inc. Presents at Bank of America Merrill Lynch 2015 Health Care Conference, May-13-2015 08:00 AM

Tokai Pharmaceuticals, Inc. Presents at Bank of America Merrill Lynch 2015 Health Care Conference, May-13-2015 08:00 AM. Venue: Encore at the Wynn, 3131 S Las Vegas Blvd, Las Vegas, Nevada, United States.

Tokai Pharmaceuticals, Inc. Announces Consolidated Earnings Results for the First Quarter Ended March 31, 2015

Tokai Pharmaceuticals, Inc. announced consolidated earnings results for the first quarter ended March 31, 2015. For the quarter, loss from operations was $13,300,000 compared to $4,892,000 a year ago. Net loss was $13,260,000 or $0.59 basic and diluted per share compared to $4,847,000 or $9.79 basic and diluted per share a year ago. The per share results were skewed by an increase in outstanding shares to 22 million from 495,049. Research and development expenses were $10.6 million compared to $3.6 million in the first quarter of 2014.

Tokai Pharmaceuticals Announces Preclinical Results from the University of Maryland Showing Galeterone and Analogs Inhibit Pancreatic Cancer Cell Growth

Tokai Pharmaceuticals, Inc. announced that scientists in the laboratory of Vincent Njar, PhD, at the University of Maryland School of Medicine presented preclinical data showing that galeterone and novel analogs of galeterone inhibited growth, survival and migration of human pancreatic ductal adenocarcinoma (PDAC) cells. These data were presented in a poster presentation titled, 'Galeterone and Its Novel Analogs Induce Profound Anti-Cancer Activities in Human Pancreatic Cancer Cell Lines,' abstract number 1764, at the 2015 American Association for Cancer Research (AACR) in Philadelphia, Pennsylvania. Galeterone and its novel analogs were found to reduce PDAC cell proliferation, cell viability, and colony formation ability using both gemcitabine-naïve and gemcitabine-resistant cell lines and also acted synergistically with gemcitabine to further enhance anti-proliferative effects. Additional in vitro assays demonstrated that galeterone and its analogs reduced tumor cell migration, invasion and reduced MMP9 secretion. At a molecular level, galeterone modulated oncotargets and translational machinery, including the Mink1/2-eIF4E axis.

Similar Private Companies By Industry

Company Name Region
Lonza Rockland, Inc. United States
Altammune Inc. United States
International Oilseed Distributors, Inc. United States
ProMab Biotechnologies, Inc. United States
Hairbiotech Inc United States

Recent Private Companies Transactions

Type
Date
Target
No transactions available in the past 12 months.
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
Bertelsmann AG Europe
NYC2012, Inc. United States
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Tokai Pharmaceuticals, Inc., please visit www.tokaipharma.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.